Venture Technologythey want $5000 + a year to subscribe…
Beginning Dec. 31st, one little-known company could receive worldwide approval for a new medical treatment that will successfully treat 50% of patients with the worst disease faced by U.S. seniors and retirees.
The stock could soar 200% once approval comes through. Three times your money… on a single investment right now.
We’re sharing the full details in Venture Technology
I searched it at stockgumshoe and could not find a reference…. confident of their product, I believe, they have offered two years free access for the purchase of one year subscription…
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Wow, $5,000 is one of the highest subscriptions around…. and they’re only offering one suggestion to start…. which they say “could” be approved.
I’m so glad I found Stock Gumshoe, Travis and the Thinkolator and the Gummies who think these things through just to help the community.
Maybe we should /could figure out what the disease is, now that the high blood pressure guidelines are lower than they were last week. The mystery stock “could … treat 50% of patients with the worst disease faced by U.S. seniors and retirees”.
Is Ventyre Technology a typo for Venture Technology?
$VRAY (full position)
I’m guessing Varian or ViewRay. More investigation will make this one obvious…
I’m went ViewRay but admit my diligence was (somewhat) quick.